Document:

Exhibit 10.91

 

September 5, 2012

 

Eno Research and Consulting Services, LLC

P.O. Box 340

Hillsborough, NC 27278

Attn:   Dr. James Flowers

             President & Chief Scientific Officer

 

Dear Dr. Flowers:

 

This letter agreement is intended to memorialize
the understanding and agreement by and between VG Energy, Inc., a Delaware corporation and a subsidiary of Viral Genetics, Inc.
("VGE"), and Eno Research & Consulting Services, LLC, a North Carolina limited liability company acting through its
division, Eno Research Chemicals & Custom

Synthesis Group ("Eno").

 

That understanding and agreement is as follows:

 

	1.		Eno and VGE hereby agree that Eno shall provide certain Custom Synthetic, Packaging
and Distribution/Fulfillment services to VGE in accordance with and pursuant to the attached Terms and Conditions (the "Terms
and Conditions"). The Terms and Conditions are incorporated herein by reference and shall constitute an integral park of
this letter agreement.

 

	2.		Promptly after the execution and delivery of this letter agreement and the payment
by VGE of the retainer/deposit contemplated by Section 3 of the Terms and Conditions, Eno and VGE shall agree on a schedule for
the production and deliver of the synthetic Sodium Oxamate.

 

	3.		As outlined in the existing Confidentiality - Non-Compete - Non-Circumvent Agreement
(the "NDA") between Eno and VGE, Eno acknowledges an understanding of VGE's Intellectual Property ("IP") surrounding
the use of Sodium Oxamate within the scope of Lipid Trigger mechanisms Eno further acknowledges and agrees that this letter agreement
shall govern the manufacturing, packaging and distribution of Sodium Oxamate by Eno for VGE to market for the purpose of commercializing
this IP. Eno will not knowingly produce Sodium Oxamate for any other person or entity for any use protected by VGE IP and/or patents
and will exercise due diligence and will use all best efforts to prevent any such violation of VGE's IP. This agreement does not
include the manufacture of Sodium Oxamate by Eno to be used for any other purpose other than what is described or prohibited by
this letter agreement.

 

	4.		This letter agreement may not be assigned by either party without the prior written
consent of the other party. This letter agreement shall be binding upon and inure to the benefit of teach of Eno and VGE and their
respective successors and permitted assigns.

 

	5.		This letter agreement shall be governed by and construed in accordance with the laws
of the State of Delaware, applicable to agreements made and to be performed therein, without reference or regard to any of its
conflicts or choice of law principles which could result in the application of the laws of another jurisdiction.

 

	6.		This letter agreement may not be amended, modified or waived, except by an instrument
in writing signed by each of Eno and VGE. This letter agreement, together with the Terms and Conditions and the NDA, constitutes
the entire understanding and agreement between Eno and VGE with respect to the subject matter hereof (whether written or oral),
and it supersedes in their entirety all prior and/or contemporaneous understandings and agreements with respect to such subject
matter, all of which are merged herein.

 

	7.		This letter agreement may be executed in multiple counterparts, each of which shall
constitute an original and all of which, when take together, shall constitute one and the same document and agreement. Facsimile
signatures and copies of this agreement shall be deemed to be valid and legal for all purposes.

 

Please evidence the agreement and
concurrence of Eno to this letter agreement, by executing and returning the attached counterpart of this letter agreement.

 

Very truly yours,

 

VG
Energy, Inc.

 

By: /s/ Haig Keledjian

Name: Haig
Keledjian

Title:  President 

Date: 9/12/2012

 

Accepted and Agreed

 

Eno Research & Consulting Services, LLC

 

By: /s/ James L. Flowers

Name: James L. Flowers

Title: President & Chief Scientific Officer

Date: September 5, 2012

 

    	1

    	 

    

 

TERMS AND CONDITIONS

 

This offer for custom synthetic and
packaging services, made by Eno Research & Consulting Services, LLC ("Eno") to Viral Genetics Energy, Inc. ("VGE"),
is subject to the following terms and conditions:

 

1.     
The compound Sodium Oxamate will be produced by Eno Research Chemicals & Custom Synthesis Group, a division of Eno Research
& Consulting Services, LLC, and will be produced using cGMP standards but are not intended for direct human consumption. Since
no specification for the product containers or closures were provided, the product will be packed in industry-standard, size-appropriate
"widemouth"-style HDPE containers with a lined, screw-cap type closure. Label designs will be finalized and submitted
to Haig at VGE within ten days of contract execution. Any stylistic or content revisions to the label must be returned to Eno within
the ten days following to prevent possible production delays resulting from delayed printing.

 

2.     
Estimated time of delivery will be 3-5 weeks from execution of agreement and payment of 50% deposit. However, this is to
be considered a binding estimate, not a guarantee. All custom synthetic projects carry some uncertainty, and while we have conditions
for this particular synthesis established in our manufacturing facility and appropriate SOP's prepared for it's production, analysis
and packaging, this project also involves placing orders for components, packaging and ingredients — all of which are currently
readily available but availability can change at any time between now and initiation of the project. Best efforts will he utilized
to maintain this schedule and full consideration has been made for: (1) the custom printed labels — which necessarily includes
preparation and production time plus delivery time; (2) the packaging components — we are using standard stock-type components
but could require shipping and might unexpectedly go on backorder: and (3) time for delivery of finished goods. However, unforeseen
synthetic difficulties occasionally arise on larger magnitude scaleup of a project such as this, as do interruptions in supply
and delivery chains. In the unlikely event this should occur, Eno will notify VGE of any anticipated delay within 24 business hours
of Eno becoming aware of the possible or impending delay, and will make every reasonable effort to keep any such delay to a minimum.
Eno will inform VGE of updated timetables.

 

3.      As
requested, Eno agrees to produce fifty 10g units at a cost of $10,300, or $206 each, and five 500g units at a cost of $8,750,
or $1750 each. This price quote for the described units is good until September 30, 2012 and has been calculated at
a "Bulk Discount" rate, based on the assumption of significant increases in sales volume after launch. For future
orders of the same unit sizes and quantities, the pricing shall remain the same as quoted unless costs associated with
producing these units change, resulting in a need for adjustment to pricing. Eno will notify VGE, in writing, of any changes
in pricing structure as soon as practical after such need has been determined. Reasonable efforts will be made to give VGE at
least two weeks notice of any pricing changes taking effect, unforeseeable market fluctuations excepted. If the unit size
and/or quantity requested changes, Eno will negotiate in good faith with VGE to establish pricing for the new units or
quantities to remain in keeping with the established price structure. All syntheses will be done at cGMP standards and all
analyses to cGLP standards. No work proposed under this agreement will commence prior to receipt of the prior agreed-to 50%
retainer/deposit. Payment of this deposit and signatures accepting these terms and conditions shall constitute execution of
the agreement. The balance due for the synthetic and packaging portion of the project shall be paid upon completion of
project but prior to shipment of finished products.

 

    	2

    	 

    

 

4.   
All products will be fully characterized and analytically verified by multinuclear NMR, HPLC, mass spectrometry and/or elemental
analyses. Copies of said analyses will be made available upon request. An MSDS, Certificate of Analysis and a Certificate of Origin
will be provided for all products synthesized, packaged or shipped by Eno.

 

5.   
Recommended storage and handling instructions for each compound produced, packaged or shipped by Eno will be included along
with the product when shipped to either VGE or its designee(s) and/or consumers. The liability of Eno under this agreement shall
be limited to replacement of the product should it arrive in unusable condition due to shipping errors and/or handling mishaps,
but not for product mishandled or improperly stored by end users, other warehouse sites or distributors.

 

7.   
By purchasing this service, VGE implies that its representatives, employees and/or their designee(s) are properly trained
in the care and handling of such products. In addition, VGE agrees to allow only those with appropriate training to handle and
use these products and will store them in a safe and environmentally sound manner.

 

8.    Eno
also agrees to negotiate in good faith a distribution and fulfillment contract with VGE using standard industry terms
and costs, to facilitate delivery of this product to VGE's intended consumers Final pricing will he determined by
combining Handling Charges (defined as the cost of labor time and shipping/packing materials) with the Shipping Charges, as
calculated by an appropriate API module (USPS, FedEx or UPS) which is to be inserted into the VGE sales/checkout web page.
These fees will be collected from the consumer by VGE and paid to Eno on a weekly to bi-weekly basis, depending on Sales
Volume.

 

Handling Charges Estimate

 

For one single shipping cartons per order:

$4.83 per Small-1, Small-2 or Medium-1 shipping
cartons

$6.77 per Medium-2, Medium-3 or Medium-4 shipping cartons

$7.31 per Large-1 and above shipping cartons

 

For multiple shipping cartons per order:

$2.21 for each additional Small-1, Small-2 or
Medium-1 shipping carton

$3.90 for each additional Medium-2, Medium-3 or Medium-4 carton

$4.51 for each additional Large-1 and
above carton

 

Freight or pallet quantity orders will
be addressed individually, as-needed.

 

    	3

    	 

    

 

9.     
Eno and its employees will be available to VGE for contract consulting on regulatory and manufacturing matters related to
the manufacture, packaging and distribution of Sodium Oxamate, as might be required by VGE, with a schedule of rates to be negotiated
in good faith based on prevailing rates at the time of service.

 

10.     
Eno
also agrees to assume the role of "Contract Manufacturing Facility" for VGE on an on-going basis, if desired, needed
and/or requested by VGE, upon mutual agreement of terms to he negotiated in good faith at the time services are requested.

 

11.     
Any
payment to Eno shall be made via bank wire, transfer or ACH transfer to the account designated by Eno, unless otherwise arranged
in advance. Should payment by check be made, up to ten (10) business days may be required before payment is "posted"
as credit to VGE's account, depending on bank regulations and processing times.

 

12.     
All
questions and comments should be addressed to Dr. James Flowers, the President & Chief Scientific Officer of Eno Research
& Consulting Services, LLC, by telephone at 919-521-5884 (office), 919-904-0783 (mobile), or 919-636-0064 (personal/after
hours); or by mail at P.O. Box 340, Hillsborough, NC 27278.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	4Exhibit 10.92

 

SUBSCRIPTION AGREEMENT

 

 

VIRAL GENETICS, INC.

2290 Huntington Drive, Suite 100

San 'Marino, CA
91108

 

 

THE
COMMON STOCK OF VIRAL GENETICS, INC., INCLUDING THAT ACQUIRABLE UPON EXERCISE OF THE WARRANTS, DESCRIBED IN THIS SUBSCRIPTION AGREEMENT
(this "Agreement") HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED ("Act"), OR QUALIFIED
UNDER THE STATE SECURITIES LAWS OF ANY STATE THE SECURITIES ARE BEING SOLD IN RELIANCE ON EXEMPTIONS FROM SUCH REGISTRATION AND
QUALIFICATION REQUIREMENTS. THE SECURITIES AND RIGHTS PURSUANT TO THIS AGREEMENT CANNOT BE SOLD, TRANSFERRED, ASSIGNED, OR OTHERWISE
DISPOSED OF, EXCEPT IN COMPLIANCE WITH APPLICABLE FEDERAL AND STATE SECURITIES LAWS, INCLUDING REGULATION S PROMULGATED UNDER THE
ACT.

 

ALL
OFFERS AND SALE OF SAID SECURITIES BY NON-U.S. PERSONS PRIOR TO THE .EXPIRATION OF A PERIOD COMMENCING ON THE DATE OF THE CLOSING
OF THIS OFFERING AND ENDING ONE-YEAR THEREAFTER SHALL ONLY BE MADE IN COMPLIANCE WITH THE SAFE HARBOR CONTAINED IN REGULATION 5,
PURSUANT TO THE REGISTRATION PROVISIONS UNDER THE SECURITIES ACT OF 1933, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION, AND ALL
OFFERS AND SALES AFTER THE EXPIRATION OF THE ONE-YEAR PERIOD SHALL BE MADE ONLY PURSUANT TO REGISTRATION OR AN EXEMPTION FROM REGISTRATION.

 

This
Agreement shall constitute the irrevocable offer of the undersigned to purchase, in the amounts and subject to the terms set forth
in this Agreement, 5,000,000 shares of the Common Stock of Viral Genetics, Inc., a Delaware corporation (the "Company")
("Shares"), for the Purchase Price of $0.001 per Share. On execution by both parties, this Agreement shall become a
bilateral agreement binding on both the undersigned and the Company Each part of this Agreement must be completed by the undersigned
and, by execution below, the undersigned acknowledges that it understands that the Company is relying on the accuracy and completeness
hereof in complying with its obligations under applicable securities laws.

 

On
the foregoing, it is hereby agreed as follows:

 

1.              SUBSCRIPTION.
The undersigned hereby irrevocably subscribes for the purchase of the Shares. The undersigned is tendering to the Company:

 

(a)               one signed copy of this Agreement; and 2

 

(b)               payment in the amount of $5000 (the "Purchase Trace"), representing $0.001 per Share,

 

2.              GENERAL
REPRESENTATIONS OF SUBSCRIBER. The undersigned hereby represents and warrants as follows:

 

(a)               The
undersigned is over the age of 18 years;

 

    	1

    	 

    

 

(b)               The
undersigned acknowledges that neither the United States Securities and Exchange Commission nor the securities commission of any
state or other federal agency has made any determination as to the merits of purchasing these securities;

 

(c)               The
undersigned has received and read, or had opportunity to do same, all of the Company's filings made on the OTCIQ News and Disclosure
system and available at www.otcmarkets.com including the "Quarterly Report" and "Consolidated Financial
Statements" for the nine months ended September 30, 2011; the "Annual Report" and "Consolidated Financial
Statements" for the fiscal year ended December 31, 2011; the "Initial Company Information and Disclosure Statements"
for the nine months and three months ending September 30, 2009 and March 31, 2009, respectively; the "Articles of Incorporation
Amendment" filed May 15, 2009; and the "Supplemental Information — Current Reporting Obligations Filing —
Merger" filed April 24, 2009; as well as all prior filings made on the SEC EDGAR. system including, without limitation, the
Form 10-KSB, as amended, for the fiscal year ended December 31, 2006, the Quarterly Report on Form l0-QSB for the quarter ended
September 30, 2007, all Current Reports on Form 8-K, all other filings and disclosures made on the OTCIQ News and Disclosure system
and available at www.otcmarketscom, all press releases, and other information; and the undersigned understands the risk
of an investment in the Company, acknowledging that an investment in the Company inherently involves high risks.

 

(d)               The undersigned, either alone or with the assistance of one or more advisers engaged by it, has such knowledge and experience
in business and financial matters that it or they is capable of evaluating the Company, its business operations, and the risks
and merits of an investment in the Company;

 

(e)               The undersigned has been provided with all materials and information requested by the undersigned or its representatives,
including any information requested to verify any information furnished, and the undersigned has been provided the opportunity
for direct communication between the Company and its representatives and the undersigned and its representatives regarding the
purchase made hereby, including the opportunity to ask questions of and receive answers from the Company including with regards
to any of the information described in 2 (c) above;

 

(f)               All
information which the undersigned has provided to the Company or its agents or representatives concerning the undersigned's
suitability to invest in the Company is complete, accurate, and correct as of the date of the undersigned's signature on this
Agreement. Such information includes, but is not limited to, information concerning the undersigned's personal financial
affairs, business position, and the knowledge and experience of the undersigned and the undersigned's advisers;

 

(g)               The
undersigned has no present intention of dividing any of the securities or the rights under this Agreement with others or of reselling
or otherwise disposing of any portion of the securities, either currently or after the passage of a fixed or determinable period
of time or on the occurrence or nonoccurrence of any predetermined event or circumstance;

 

(h)               The
undersigned was at no time solicited by any leaflet, public promotional meeting, circular, newspaper or magazine article, radio
or television advertisement, or any other form of general advertising or solicitation in connection with the offer, sale, or purchase
of the securities through this Agreement; and

 

(i)               The
undersigned has adequate means of providing for its current needs and possible contingencies and has no need now and anticipates
no need in the foreseeable future, to sell any portion of the securities for which the undersigned hereby subscribes. The undersigned
is able to bear the economic risks of this investment and consequently, without limiting the generality of the foregoing, is able
to hold the securities for an indefinite period of time, and has a sufficient net worth to sustain a loss of the entire investment,
in the event such loss should occur.

 

    	2

    	 

    

 

(j)               The
undersigned is an Accredited Investor, and has completed the following Accredited Investor Qualifying Questionnaire:

 

PERSONAL
FINANCIAL INFORMATION. The following information pertaining to the undersigned as a natural person and U.S. Persons
within the meaning of Regulation S is being provided here in lieu of furnishing a personal financial statement.

 

(a)               
My individual net worth, or joint net worth with my spouse, excluding any primary residence, exceeds $1,000,000.

Yes [X]     No
[  ] 

RW

INITIAL

 

(b)               
My individual income in 2010 and 2011 exceeded $200,000 in each such year, and I reasonably expect my individual income will be
in excess of $200,000 in 2012.

Yes [   ]     No [  ]

INITIAL

 

(c)                The
joint income of my spouse and I in 2010 and 2011 exceeded $300,000 in each such year, and I reasonably expect our joint
income will be in excess of $300,000 in 2012.

Yes [   ]     No [  ]

INITIAL

 

(d)                Considering
the foregoing and all other relevant factors in my financial and personal circumstances, I am able to bear the economic risk
of an investment in the Company.

Yes [X]     No
[  ]

RW

INITIAL

 

3.              REPRESENTATIONS
REGARDING EXEMPTIONS AND RESTRICTIONS ON TRANSFER. The undersigned represents that the securities are being acquired
without a view to, or for, resale in connection with any distribution of the securities or any interest therein without
registration or other compliance under the Act, and that the undersigned has no direct or indirect participation in any such
undertaking or in the underwriting of such an undertaking. The undersigned understands that the securities have not been
registered, but are being acquired by reason of a specific exemption under the Act as well as under certain state statutes
for transactions by an issuer not involving any public offering and that any disposition of the securities may, under certain
circumstances, be inconsistent with this exemption and may make the undersigned an 'underwriter' within the meaning of the
Act. The undersigned acknowledges that the securities mast be held and may not be sold, transferred, or otherwise disposed of
for value unless they are subsequently registered under the Act or an exemption from such registration is available. The
Company is under no obligation to register the securities under the Act or under Section 12 of the Securities Exchange Act of
1934, as amended. The certificates representing the securities will bear a legend restricting transfer, except in compliance
with applicable federal and state securities statutes.

 

    	3

    	 

    

 

4.              GENERAL.
The undersigned further understands, acknowledges, and agrees that:

 

(a)               This
Agreement is registered in the name of the undersigned on the books of the Company at its principal offices, and no transfer
hereof shall be valid and binding on the Company unless made at such offices by the registered holder or his attorney-in-fact
duly authorized in writing. The Company may deem and treat the person in whose name this Agreement is registered as the
absolute owner hereof for the purpose of receiving any securities issuable pursuant hereto and for all other purposes.

 

(b)               This Agreement shall be construed in accordance with and governed by the laws of the state of California.

 

(c)               This Agreement constitutes the entire agreement between the parties respecting the subject matter hereof.

 

(d)               Notwithstanding any of the representations, warranties, acknowledgments, or agreements made herein by the undersigned, the
undersigned does not waive any rights granted to the undersigned under federal and state securities laws.

 

(e)               The
undersigned will hold title to the securities as follows:

 

______
Community Property

 

______
Joint Tenants, with Right of Survivorship

 

______
Tenants in Common

 

______
Separate Property

 

___X__
Other   Single Person

                   (Single
Person, Trust, Etc., Please Indicate)

 

 

 

    	4

    	 

    

 

 

 

 

 

 

 

 

 

    	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]